Impact of corneal cross-linking combined with photorefractive keratectomy on blurring strength

Georgios Labiris1,2
Haris Sideroudi2
Dimitris Angelonias2
Kimonas Georgantzoglou2
Vassilios P Kozobolis1,2
1Department of Ophthalmology, University Hospital of Alexandroupolis, 2Eye Institute of Thrace, Alexandroupolis, Greece

Purpose: The aim of this study was to evaluate the impact of corneal cross-linking combined with photorefractive keratectomy (PRK) on blurring strength.

Methods: A total of 63 patients with keratoconus were recruited for this study, and two study groups were formed according to the therapeutic intervention: corneal collagen cross-linking (CxL) group (33 patients) received corneal cross-linking according to the Dresden protocol, while the rest additionally received topography-guided photorefractive keratectomy (tCxL). The impact of surgical procedure on blurring strength was assessed by power vector analysis. Potential association between blurring strength and vision-specific quality of life was assessed using the National Eye Institute Visual Function Questionnaire (NEI-VFQ) 25 instrument.

Results: Blurring strength presented excellent correlation with NEI-VFQ scores both preoperatively and postoperatively (all \( P < 0.01 \)). Both groups demonstrated nonsignificant changes in best-corrected visual acuity; however, only the tCxL group had significant reduction in blurring strength \((13.48 \pm 10.86 \text{ [preoperative]}, 4.26 \pm 7.99 \text{ [postoperative]}, P = 0.042)\).

Conclusion: Only the combined treatment (tCxL) resulted in significant reduction in blurring strength. Moreover, the excellent correlation of blurring strength with NEI-VFQ scores indicates its reliability as an index of self-reported quality of life in keratoconus, since it seems to address the nonsignificant changes in best-corrected visual acuity following CxL treatments that are conceived as subjective improvement by the patient.

Keywords: keratoconus, cornea crosslinking, blurring strength, tCxL

Introduction

It is documented that keratoconus (KC) is associated with complex refractive errors that conventional refractive solutions (ie, spectacles or contact lenses) cannot fully address. In fact, KC’s complex refractive status is among the primary reasons for the overall reduction in visual capacity, even in the early stages of the disease.1–4 A series of methods have been proposed for the quantification of KC-associated refractive error in clinical settings. Among the prevalent ones is power vector analysis. Power vector analysis introduces a single measurable unit, the blurring strength \((B)\), which is the outcome of the geometrical representation of spherocylindrical refractive errors in three fundamental dioptric components. The conceptual advantage of power vectors and especially of \(B\) is that as they simplify the changes in the optical characteristics of the eye due to either KC progress or a surgical intervention.5–7

Corneal collagen cross-linking (CxL) was recently developed in order to stabilize and strengthen the ectatic cornea by creating new covalent bonds between stromal collagen fibrils in the anterior 200–300 \( \mu \text{m} \) of the corneal stroma. Moreover, in an attempt to (partially) reverse KC’s impact on visual capacity, CxL has been combined...
with topography-guided photorefractive keratectomy (tCxL) with excellent results regarding safety and patients’ satisfaction.\(^8\)\(^-\)\(^11\)

However, the additional beneficial impact of tCxL on the refractive status as reflected by power vectors has not been studied in clinical trials. Therefore, within this context, the primary objective of this study was to assess the impact of both CxL and tCxL on blurring strength in a sample of patients with KC. The objective of this study was to assess the correlation between (B) and vision-specific quality of life (VS-QoL) 5-list-item Greek version of the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).\(^12\)

**Patients and methods**

**Setting**

This study was a prospective, observational, nonrandomized trial (ClinicalTrials.gov Identifier: NCT01527721). The study adhered to the tenets of the Declaration of Helsinki, and written informed consent was given by all participants. The institutional review board of the Democritus University of Thrace approved the protocol, and the study was conducted at the Eye Institute of Thrace, Alexandroupolis, Greece.

**Participants**

Patients with KC were recruited from the Outpatients Cornea service of the Eye Institute of Thrace, and two study groups were formed which are as follows: 1) tCxL (study) group and 2) CxL (control) group. All participants with KC with progressive KC in consecutive corneal topographies and changes in the refractive power had to present. Exclusion criteria included glaucoma, suspicion for glaucoma, intraocular pressure-lowering medications, central corneal thickness <400 μm, K-readings >60 D, history of herpetic keratitis, corneal scarring, severe eye dryness, pregnancy or nursing, current corneal infection, or underlying autoimmune disease. The tCxL group participants underwent combined tCxL with CxL, while the CxL group underwent standard CxL treatment according to the Dresden protocol. In order to be eligible for the tCxL group, participants should have central corneal thickness >450 μm.

**Surgical procedure**

The same surgical procedure was applied to all the patients with KC, which included instillation of proparacaine hydrochloride 0.5% drops (Alcaíne\(^®\); Alcon, Inc., Hünenberg, Switzerland) for topical anesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds, and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled into the cornea for 30 minutes (two drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The ultraviolet (UV) radiation source was UV-XTM (IROC AG, Zürich, Switzerland). In detail, an 8.0 mm diameter of central cornea was irradiated for 30 minutes by ultraviolet A (UVA) light with a wavelength of 370 nm and an irradiance of 3 mW/cm\(^2\). Instillation of riboflavin drops (one drop every 2 minutes) was continued during the irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution was applied every 6 minutes to moisten the cornea.

For the tCxL group, tCxL preceded the CxL. The epithelium was mechanically removed with a hockey knife, and ablation was performed in a 9.0 mm zone with a maximal intended depth of 50 μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation, we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight Laser Technologie, AG, Erlangen, Germany) with the T-CAT\(^®\) ablation profile.

**Postoperative management**

After treatment, all patients were prescribed topical ofloxacin 0.3% drops qid (Exocin; Allergan, Inc., Irvine, CA, USA) and fluorometholone qid (Flucon; Alcon, Inc.), accompanied by frequent instillation of artificial tears (Tears Naturale II, Alcon, Inc.). Soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected. Follow-up visits were performed on the first day, seventh day, first month, third month, sixth month, and 12th month after the operation.

**Data collection**

Regarding Scheimpflug camera (Pentacam Classic; OCU-LUS Optikgerate GmbH, Heidelberg, Germany; software version 1.14r04) measurements, acceptable maps had at least 10.0 mm of corneal coverage. Moreover, images with extrapolated data in the central 9.0 mm zone were excluded. Regarding the measuring procedure itself, patients were asked to blink and then look at the fixation device. In the case of low-quality image, the procedure was repeated until the acceptable criteria were met.

The impact of the surgical technique (either CxL or tCxL) on spherocylindrical error was evaluated by power vector analysis as described earlier.\(^6\)\(^-\)\(^13\) Power vectors are a geometrical representation of spherocylindrical refractive errors in three fundamental dioptric components. Manifest
refractions comprising sphere (S), cylinder (C), and axis (A) were converted into three dioptric powers (M, J, and J). Moreover, we calculated the overall blurring strength (B) of the spherical-cylindrical error by measuring the length of the produced vector\(^ {14,15}\) derived by the following formulas:

\[
M = S + C/2; J = (-C/2) \cos(2\varphi) \tag{1}
\]

\[
J = (-C/2) \sin(2\varphi) \tag{2}
\]

\[
B = (M^2 + J^2 + J^2)^{1/2} \tag{3}
\]

VS-QoL was obtained for all participants using the NEI VFQ-25. All data for analysis were obtained at the last follow-up visit.

**Statistical analysis**

Normality of the measured data was assessed using Kolmogorov–Smirnov test, and parametric or nonparametric tests were applied, as necessary. An a priori power analysis was performed. For an effect size of 0.74, 30 participants would be required in each group for the study to have a power of 0.8 at the significance level of 0.05. All statistical analysis was performed using the MedCalc statistical program (version 9.6.2.0; MedCalc Software, Mariakerke, Belgium).

**Results**

A total of 63 patients (29 females and 34 males) with progressive KC were included in the study. Of them, 33 patients underwent CxL treatment (CxL group), while the remaining 30 patients underwent combined CxL and tCxL (tCxL group). According to Table 1, study groups presented nonsignificant differences in age, best-corrected visual acuity (BCVA), defocus equivalent, mean power vectors, blurring strength, and subjective assessment of VS-QoL (P=0.404). Moreover, VS-QoL scores demonstrated excellent correlation with blurring strength for both study groups (CxL: R\(^2\): 0.679; tCxL: R\(^2\): 0.654, P<0.001).

Regarding the impact of CxL and tCxL on spherical-cylindrical error (Table 2), power vector analysis indicated that tCxL reduced blurring strength (13.48±10.86 [preoperative], 4.26±7.99 [postoperative], P=0.042) primarily due to the reduction in the M component (−3.55±2.32 [preoperative], −1.30±2.6 [postoperatively], P=0.043). On the other hand, nonsignificant impact on the overall blurring strength could be detected in the CxL group, despite changes in the J component (P=0.418). Blurring strength continued to demonstrate excellent association with NEI-VFQ 25 scores (Figure 1); however, R\(^2\) values were slightly reduced when compared to preoperative ones. Moreover, both groups had a significant improvement in VS-QoL (tCxL: 91.07±13.11, P<0.001; CxL: 89.95±15.68, P=0.045); however, a significant difference could be detected in VS-QoL postoperative intergroup comparison, as well (P=0.012). The latter finding suggests that the tCxL group perceives better the beneficial impact of the corresponding surgical technique.

**Discussion**

CxL treatment has been proven to be an effective therapeutic approach for progressive KC, leading to stabilization of corneal ectasia by enhancing corneal rigidity.\(^ {16–18}\) However, the technique aims in the stabilization of the progressive ectasia and does not address any pre-existing poor visual performance due to the high irregularity of the ectatic cornea. Therefore, a series of refractive therapeutic techniques were combined with CxL in an attempt to address both the progression and the underlying complex refractive error. Among these combined treatments are: CxL combined with intracorneal ring segments,\(^ {19,20}\) CxL combined with conductive keratoplasty,\(^ {21}\) and CxL combined with PRK.\(^ {22,23}\) Recently, CxL was combined with both intracorneal rings and PRK.\(^ {24}\)

In fact, the tCxL component of the combined CxL-PRK treatment only partially addresses the complex refractive error, primarily due to the limitations of the preoperative pachymetry,\(^ {25,24}\) the necessary residual bed for safe CxL,\(^ {27}\) and eventually due to the fact that specific guidelines are yet to be introduced. Despite these limitations, recent studies indicated the additional beneficial impact over conventional CxL in terms of visual recovery and subjective improvement in the quality of vision.\(^ {10,11,25}\)

---

**Table 1 Preoperative patient characteristics**

| Parameter                  | Mean ± SD  | tCxL group | CxL group | P-value |
|----------------------------|------------|------------|-----------|---------|
| Age (years)                | 27.2±6.6   | 31.2±11.1  | 0.223     |         |
| BCVA (log MAR)             | 0.14±0.11  | 0.20±0.17  | 0.161     |         |
| Defocus equivalent (D)     | 6.30±3.36  | 6.25±5.10  | 0.492     |         |
| Mean power vectors (D)\(^ {*}\) | | | | |
| M                         | −3.35±2.32 | −4.21±4.32 | 0.369     |         |
| J                          | 0.40±0.70  | 0.10±1.30  | 0.412     |         |
| J                          | −0.14±2.24 | 0.51±1.87  | 0.303     |         |
| B                          | 13.48±10.86 | 19.26±25.90 | 0.305     |         |
| NEI-VFQ25 score            | 85.85±12.34 | 84.22±11.98 | 0.404     |         |
| R\(^{2}\) (NEIFVFQ25 score/B) | 0.654     | 0.679      | <0.001\(^ {*}\) \*  |

**Notes:** \(^ {*}\)Statistically significant, \(^ {*}\)Indicates significant correlation. \(^ {*}\)Manifist refractions comprising sphere (S), cylinder (C), and axis (A) were converted into power vector coordinates \((M, J, J)\) and blurring strength \((B)\) by the following formulas: \(M = S + C/2; J = (-C/2) \cos(2\varphi); J = (-C/2) \sin(2\varphi); B = (M^2 + J^2 + J^2)^{1/2}\).}

**Abbreviations:** BCVA, best-corrected visual acuity; NEI-VFQ, National Eye Institute Visual Function Questionnaire; SD, standard deviation.
Further to the prevalent indexes of visual performance (ie, UVA, BCVA, and spherical equivalent) which are frequently used in CxL studies, we attempted to explore the impact of CxL and CxL combined with PRK on blurring strength. It is known that power vector analysis is an efficient method for evaluating refractive surgery outcomes with the transformation of manifest and topographic refractions into power vectors. Power vectors allow us to directly evaluate the impact of an intervention on refraction by mathematically comparing the impact on its independent components ($M$, $J_0$, $J_{45}$).

$5–7$

Regarding our study, all participants underwent either CxL or combined CxL with tCxL treatments, with no signs of disease progression for the first year of follow-up. Moreover, both groups presented nonsignificant improvement in BCVA. Therefore, in clinical terms, both treatments were considered satisfactory. However, tCxL participants experienced an additional significant reduction in blurring strength and improvement in UVA that CxL participants did not. The clinical importance of this finding is that even though tCxL targets to a maximal depth of 50 µm and cannot address the underlying refractive error as a whole, it has a significant beneficial impact on blurring strength, since the latter is comprised by the square root of the powers of the individual components ($M$, $J_0$, $J_{45}$). In simple words, minor treatment changes of the axis and power of astigmatism and of the spherical component induce major changes on the blurring strength.

Former publications from our group indicated the significant beneficial impact of CxL (either stand-alone CxL or combined with tCxL) on self-perceived, VS-QoL. $10,23$
In this study, we confirmed the former results; moreover, we identified blurring strength as an excellent index of the efficacy of both approaches (CxL and tCxL) since it demonstrated excellent correlation with NEI-VFQ scores. Our findings are consistent with former studies that identified dioptric blur’s impact on reading ability and contrast sensitivity. $28$

Within this context, the prospective clinical usefulness of blurring strength in tCxL treatments becomes apparent. Preoperative calculation of the potential postoperative blurring strength provides essential information regarding the exact parameters

### Table 2 Postoperative clinical data

| Parameters                  | tCxL          | $P$-value | CxL          | $P$-value |
|-----------------------------|---------------|-----------|--------------|-----------|
| BCVA                        | 0.08±0.08     | 0.104     | 0.13±0.10    | 0.101     |
| $M$                         | $-1.30±2.67$  | 0.043*    | $-3.62±2.00$ | 0.176     |
| $J_0$                       | 0.30±0.83     | 0.467     | $-0.56±1.07$ | 0.029*    |
| $J_{45}$                    | 0.47±0.55     | 0.247     | 0.17±2.04    | 0.207     |
| $B$                         | 4.26±7.99     | 0.042*    | 10.65±10.55  | 0.092     |
| NEI-VFQ 25 score            | 91.07±13.11   | 0.001*    | 89.95±15.68  | 0.045*    |
| $R^2$ (NEI-VFQ 25 score/$B$)| 0.601         | <0.001*   | 0.599        | <0.001*   |

Notes: *Statistically significant; $^*$Manifest refractions comprising sphere ($S$), cylinder ($C$), and axis ($\phi$) were converted into power vector coordinates ($M$, $J_0$, $J_{45}$) and blurring strength ($B$) by the following formulas: $M = S + C/2$; $J_0 = (-C/2) \cos(2\phi)$; $J_{45} = (-C/2) \sin(2\phi)$; $B = (M^2 + J_0^2 + J_{45}^2)^{1/2}$.

Abbreviations: BCVA, best-corrected visual acuity; NEI-VFQ, National Eye Institute Visual Function Questionnaire.

![Figure 1](https://example.com/image1.png)

Figure 1 Correlation chart of blurring strength and total NEI-VFQ 25 score for the tCxL group.

Abbreviations: CxL, corneal collagen cross-linking; NEI-VFQ, National Eye Institute Visual Function Questionnaire.
of an individualized tCXL treatment of an ectatic cornea aiming primarily to improved VS-QoL scores. The fact that BCVA remained unaffected in both study groups suggests that conventional correction methods such as spectacles or contact lenses addressed the remaining refractive error. However, clinical experience suggests that patients with KC tend to develop intolerance especially after chronic use of semi-hard or hard contact lenses and nonspecific disturbances in spectacle corrections. Therefore, any possible improvement in the dioptric blur during the surgical management of patients with KC should be attempted in order to minimize poor visual performance if or when conventional correction methods fail in the future due to intolerance.

**Conclusion**

In summary, to our knowledge, this is the first study to report on the effect of CXL and CXL combined with tCXL on the blurring strength. Moreover, it is the first study to explore the excellent association between blurring strength and self-perceived quality of life in patients with KC. Our results suggest that tCXL’s beneficial impact on blurring strength is significant; therefore, the treatment should be delivered immediately when progression is established and safety issues are resolved. Moreover, preoperative calculation of blurring strength could be a valuable adjuvant index for the PRK in combined treatments.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Camps VJ, Piñero DP, Caravaca-Arens E, de Fez D, Pérez-Cambrodí RJ, Artola A. New approach for correction of error associated with keratometric estimation of corneal power in keratoconus. *Cornea*. 2014;33(9):960–967.
2. Piñero DP, Alíó JL, Alesón A, Escaf M, Miranda M. Pentacam posterior and anterior corneal aberrations in normal and keratoconic eyes. *Clin Exp Optom*. 2009;92(3):297–303.
3. Piñero DP, Camps VJ, Caravaca-Arens E, Pérez-Cambrodí RJ, Artola A. Estimation of the central corneal power in keratoconus: theoretical and clinical assessment of the error of the keratometric approach. *Cornea*. 2014;33(3):274–279.
4. Ravikumar A, Marazzac JD, Bedell HE, Shi Y, Applegate RA. Change in visual acuity is well correlated with change in image-quality metrics for both normal and keratoconic wavefront errors. *J Vis*. 2013;13(13):2.
5. Blendowske R. Unaided visual acuity and blur: a simple model. *Optom Vis Sci*. 2015;92(6):e121–e125.
6. Thibos LN, Horner D. Power vector analysis of the optical outcome of refractive surgery. *J Cataract Refract Surg*. 2001;27(1):80–85.
7. Thibos LN, Wheeler W, Horner DG. Power vectors: an application of Fourier analysis to the description and statistical analysis of refractive error. *Optom Vis Sci*. 1997;74:367–375.
8. Parker JS, van Dijk K, Melles GR. Treatment options for advanced keratoconus: a review. *Surv Ophthalmol*. 2015;60(5):459–480.
9. Randleman JB, Khandelwal SS, Hafezi F. Corneal cross-linking. *Surv Ophthalmol*. 2015;60(6):509–523.
10. Labiris G, Giarmoukakis A, Sideroudi H, Gkika M, Fanariotis M, Kozobolis V. Impact of keratoconus, cross-linking and cross-linking combined with photorefractive keratectomy on self-reported quality of life. *Cornea*. 2012;31(7):734–739.
11. Ortiz-Toquero S, Perez S, Rodriguez G, de Juan V, Mayo-Iscar A, Martin R. The influence of the refractive correction on the vision-related quality of life in keratoconic patients. *Qual Life Res*. 2015. Epub 2015 Sep 3.
12. Labiris G, Katsanos A, Fanariotis M, et al. Psychometric properties of the Greek version of the NEI-VFQ 25. *BMC Ophthalmol*. 2008;8:4.
13. Labiris G, Gatziooufas Z, Giarmoukakis A, Sideroudi H, Kozobolis V. Evaluation of the efficacy of the Allegretto Wave and the Wavefront-optimized ablation profile in non-anterior astigmatism. *Acta Ophthalmol*. 2012;90(6):e442–e446.
14. Harris WF. Dioptric strength: a scalar representation of dioptric power. *Ophthalmic Physiol Opt*. 1994;14:216–218.
15. Raasch TW. Spherocylindrical refractive errors and visual acuity. *Optom Vis Sci*. 1995;72:272–275.
16. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. *Am J Ophthalmol*. 2003;135:620–627.
17. Wollensak G. Cross-linking treatment of progressive keratoconus: new hope. *Curr Opin Ophthalmol*. 2006;17:356–360.
18. Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. *J Refract Surg*. 2008;24(7):720–725.
19. El-Raggal TM. Sequential versus concurrent KERARINGS insertion and corneal collagen cross-linking for keratoconus. *Br J Ophthalmol*. 2011;95(1):37–41.
20. Saelens IE, Bartels MC, Bleyen I, Van Rij G. Refractive, topographic, and visual outcomes of same-day corneal cross-linking with Ferrara intracorneal ring segments in patients with progressive keratoconus. *Cornea*. 2011;30(12):1406–1408.
21. Kymionis GD, Kontadakis GA, Naoumidi TL, Kazakos DC, Giapitzakis I, Pallikaris IG. Conductive keratoplasty followed by collagen cross-linking with riboflavin-UV-A in patients with keratoconus. *Cornea*. 2010;29(2):239–243.
22. Kanellopoulos AJ, Asimellis G. Keratoconus management: long-term stability of topography-guided normalization combined with high-fluence CXL stabilization (the Athens protocol). *J Refract Surg*. 2014;30(2):88–93.
23. Labiris G, Giarmoukakis A, Sideroudi H, Kozobolis V. Impact of keratoconus, cross-linking and cross-linking combined with photorefractive keratectomy on self-reported quality of life: a 3-year update. *Cornea*. 2013;32(9):e186–e188.
24. Iovino A, Légaré ME, Rootman DB, Yeung SN, Kim P, Rootman DS. Intracorneal ring segments implantation followed by same-day photorefractive keratectomy and corneal collagen cross-linking in keratoconus. *J Refract Surg*. 2011;27(12):915–918.
25. Krueger RR, Kanellopoulos AJ. Stability of simultaneous topography-guided photorefractive keratectomy and riboflavin/UV-A cross-linking for progressive keratoconus: case reports. *J Refract Surg*. 2010;26(10):S827–S832.
26. Kymionis GD, Kounakis GA, Limnopoulou AN, Kontadakis GA, Grentzelos MA. Simultaneous topography-guided photorefractive keratectomy followed by corneal collagen cross-linking for keratoconus. *Am J Ophthalmol*. 2011;152(5):748–755.
27. Spoerl E, Hoyer A, Pillunat LE, Raiskup F. Corneal cross-linking and safety issues. *Open Ophthalmol J*. 2011;5:14–16.
28. Chung ST, Jarvis SH, Cheung SH. The effect of dioptric blur on reading performance. *Vision Res*. 2007;47(12):1584–1594.
29. Dana MR, Putz JL, Viana MA, Sugar J, McMahon TT. Contact lens failure in keratoconus management. *Ophthalmology*. 1992;99(8):1187–1192.
